Phase 2 Metastatic Breast Cancer trials recruiting now

All Metastatic Breast Cancer trials, every phase

Other phases for Metastatic Breast Cancer

Phase 2 Metastatic Breast Cancer trials

• A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
  NCT06064812 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 22 locations
• A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
  NCT07002177 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
  NCT06099769 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
  NCT06110793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
  NCT04683679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study of Surgery and Radiotherapy in People With Breast Cancer
  NCT07053085 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
  NCT06202261 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
  NCT05534438 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
  NCT06525766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
  NCT05660083 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
  NCT06324357 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 105 locations
• Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
  NCT05816655 · Phase: Phase 2 · Ages: 19 Years to 80 Years · Sex: Female · 2 locations
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
  NCT06450314 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Definitive Radiation for High-Risk Spine Metastases
  NCT06165419 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
  NCT07198724 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
  NCT06062498 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
  NCT04573231 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
  NCT05455619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
  NCT07340541 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
  NCT05693766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
  NCT06369831 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
  NCT04159818 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
  NCT05720260 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 1 location
• Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
  NCT06793553 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
  NCT03808337 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
  NCT05732051 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
  NCT07203378 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer
  NCT04965766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
  NCT03449238 · Phase: Phase 1, Phase 2 · Ages: 19 Years to 90 Years · Sex: Female · 3 locations
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  NCT07222215 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer
  NCT03591276 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
  NCT06105684 · Phase: Phase 2 · Ages: 60 Years and older · Sex: Female · 1 location
• Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
  NCT06649331 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
  NCT02422641 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
  NCT05716516 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Scalp Cooling in MBC
  NCT04986579 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
  NCT06263543 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
  NCT06409390 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
  NCT04990921 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
  NCT05846789 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.